

JUN 2 1 2000

TECH CENTER 1000/2900



CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

David J. Mangelsdorf et al.

Serial No.: 09/460,292

Filed: December 10, 1999

For: COMPOSITIONS AND METHODS OF

MODULATING CHOLESTEROL

METABOLISM

Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: UTSD:596/SLH

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Assistant

Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit

Account No.50-1212/10017652/SLH.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

Attorney for Applicants

Fulbright & Jaworski L.L.P. 600 Congress Avenue, Suite 2400 Austin, TX 78701

Date: 6/14/00

TELEPHONE: 512 418-3000
FACSIMILE: 512 74-7577
STEVEN L. HIGHLANDENDAME
PARTNER
INTERNET ADDRESS:

ULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

JUN 2 1 2000

HOUSTON
WASHINGTON, D.C
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

June 14, 2000

SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/418-3184

FILE: UTSD:596

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington DC 20231, on the date below:

June 14, 2000

Date

Steven W Highlander

Assistant Commissioner for Patents Washington, DC 20231

RE:

SN 09/460,292 "COMPOSITIONS AND METHODS OF MODULATING CHOLESTEROL METABOLISM" - David J. Mangelsdorf et al. (Client reference: UTSMC/DAL:596)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449 and references (A1-A11, B1 and C1-C70).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10017652/SHL.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L Highlander Reg. No. 37,642

SLH/cas

Encl.: As noted

256705.1